ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.63
0.12%
US Tech 100
21,156.80
-0.70%
S&P 500
6,101.24
-0.29%
US Dollar vs CAD
1.4391
-0.67%
Bitcoin
99,707.78
-2.88%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AnaptysBio Inc (ANAB) Share Price

AnaptysBio Inc

AnaptysBio Inc (ANAB)

NASDAQ
16.85
0.22
(1.32%)
Closed January 27 3:00PM
Delayed by 15 minutes
16.85
-0.03
(-0.18%)
After Hours: 6:40PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
16.85
Bid
14.87
Ask
17.94
Volume
481,092
16.24 Day's Range 17.21
12.51 52 Week Range 41.3083
Market Cap
512.723M
Previous Close
16.63
Open
16.63
Last Trade
10
@
16.01
Last Trade Time
Financial Volume
US$ 8,010,648
VWAP
16.651
Average Volume (3m)
666,476
Shares Outstanding
30,428,682
Dividend Yield
-
PE Ratio
-3.14
Earnings Per Share (EPS)
-5.38
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.anaptysbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was US$16.63. Over the last year, AnaptysBio shares have traded in a share price range of US$ 12.51 to US$ 41.3083.

AnaptysBio currently has 30,428,682 shares outstanding. The market capitalization of AnaptysBio is US$506.03 million. AnaptysBio has a price to earnings ratio (PE ratio) of -3.14.

Ask ADVFN Intelligence (AI)

AnaptysBio (ANAB) Options Flow Summary

ANAB Options Flow

Overall Flow

Bullish

Net Premium

54k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ANAB Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

January 15 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 07 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 07 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 07 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 07 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 07 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 07 2025
Edgar (US Regulatory)

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...

January 07 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

January 02 2025
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

December 18 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.519.8435462842215.3417.139915.06114165316.23637257CS
43.1522.992700729913.717.139912.5172877214.99979777CS
12-4.78-22.09893666221.6326.5112.5166647617.83531677CS
26-20.41-54.777241009137.2641.308312.5149278024.07254437CS
52-7.52-30.857611817824.3741.308312.5141556224.18329577CS
156-13.5-44.481054365730.3541.308312.5130929023.33178784CS
2602.1614.703880190614.6941.308311.9531433222.73843972CS

ANAB - Frequently Asked Questions (FAQ)

What is the current AnaptysBio share price?
The current share price of AnaptysBio is US$ 16.85
How many AnaptysBio shares are in issue?
AnaptysBio has 30,428,682 shares in issue
What is the market cap of AnaptysBio?
The market capitalisation of AnaptysBio is USD 506.03M
What is the 1 year trading range for AnaptysBio share price?
AnaptysBio has traded in the range of US$ 12.51 to US$ 41.3083 during the past year
What is the PE ratio of AnaptysBio?
The price to earnings ratio of AnaptysBio is -3.14
What is the cash to sales ratio of AnaptysBio?
The cash to sales ratio of AnaptysBio is 29.94
What is the reporting currency for AnaptysBio?
AnaptysBio reports financial results in USD
What is the latest annual turnover for AnaptysBio?
The latest annual turnover of AnaptysBio is USD 17.16M
What is the latest annual profit for AnaptysBio?
The latest annual profit of AnaptysBio is USD -163.62M
What is the registered address of AnaptysBio?
The registered address for AnaptysBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the AnaptysBio website address?
The website address for AnaptysBio is www.anaptysbio.com
Which industry sector does AnaptysBio operate in?
AnaptysBio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

ANAB Discussion

View Posts
Monksdream Monksdream 4 months ago
ANAB definite uptrend
👍️0
gfp927z gfp927z 3 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
👍️0
HighPeaks HighPeaks 3 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
👍️0
tedpeele tedpeele 3 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
👍️0
HighPeaks HighPeaks 3 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
👍️0
TFMG TFMG 5 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


👍️0
LoveItInBishop LoveItInBishop 5 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
waterchaser waterchaser 5 years ago
LOL! Twitter PnD. Buyer beware.
👍️0
420man 420man 5 years ago
Once the real bounce starts it will be fast....
👍️0
Crazy Money Crazy Money 5 years ago
$10 to da moon
👍️0
420man 420man 5 years ago
This will bounce..... 15 AH
👍️0
RJ Trotts RJ Trotts 5 years ago
trying to bounce back over $11, hoping for more
👍️0
TaxiCaT TaxiCaT 5 years ago
Ouch -
👍️0
celle celle 6 years ago
Nothing happen here?
👍️0
manny371 manny371 7 years ago
This stock is making noise! Bought in Sept $ANAB
👍️0

Your Recent History

NASDAQ
ANAB
AnaptysBio
BIT
UC3C8S
Unicredit Bank
BIT
P12X29
BNP PARIBAS ISSUANCE
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads